BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 348-355

  O'Brien, Phillipe D ^a   Hur, Junguk ^a   Hayes, John M ^a   Backus, Carey ^a   Sakowski, Stacey A ^b   Feldman, Eva L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cytokine; Diabetic neuropathy; Functional enrichment; Gene expression analysis; Inflammation; Leptin; Matrix metalloproteinase; Mouse model; Obesity; Type 2 diabetes

Indexed keywords

CXCL1 CHEMOKINE; EOTAXIN; GLUCOSE; MACROPHAGE ELASTASE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MALE; MICROARRAY ANALYSIS; MMP12 GENE; MOUSE; NERVE CONDUCTION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENE EXPRESSION PROFILING; METABOLISM; MOUSE MUTANT; PHENOTYPE; SCIATIC NERVE;

ANIMALS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PHENOTYPE; SCIATIC NERVE;

EID: 84909979541     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.10.015     Document Type: Article

References (52)

1. Belmadani A., Tran P.B., Ren D., Assimacopoulos S., Grove E.A., Miller R.J. The chemokine stromal cell-derived factor-1 regulates the migration of sensory neuron progenitors. J. Neurosci. 2005, 25:3995-4003.
2. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Kloting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Haring H.U., Schleicher E., Nawroth P.P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50:2792-2808.
3. Bierhaus A., Haslbeck K.M., Humpert P.M., Liliensiek B., Dehmer T., Morcos M., Sayed A.A., Andrassy M., Schiekofer S., Schneider J.G., Schulz J.B., Heuss D., Neundorfer B., Dierl S., Huber J., Tritschler H., Schmidt A.M., Schwaninger M., Haering H.U., Schleicher E., Kasper M., Stern D.M., Arnold B., Nawroth P.P. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest. 2004, 114:1741-1751.
4. Bolin L.M., Murray R., Lukacs N.W., Strieter R.M., Kunkel S.L., Schall T.J., Bacon K.B. Primary sensory neurons migrate in response to the chemokine RANTES. J. Neuroimmunol. 1998, 81:49-57.
5. Camara C.C., Ramos H.F., da Silva A.P., Araujo C.V., Gomes A.S., Vale M.L., Barbosa A.L., Ribeiro R.A., Brito G.A., Costa C.M., Oria R.B. Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats. Neurosci. Lett. 2013, 556:93-98.
6. Centers for Disease Control, Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
7. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Rollins B.J., Tesch G.H. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
8. Clee S.M., Nadler S.T., Attie A.D. Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. Am. J. Ther. 2005, 12:491-498.
9. Coppari R., Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug Discov. 2012, 11:692-708.
10. Dai M., Wang P., Boyd A.D., Kostov G., Athey B., Jones E.G., Bunney W.E., Myers R.M., Speed T.P., Akil H., Watson S.J., Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33:e175.
11. Fernyhough P., Roy Chowdhury S.K., Schmidt R.E. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert. Rev. Endocrinol. Metab. 2010, 5:39-49.
12. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
13. Haberstroh U., Pocock J., Gomez-Guerrero C., Helmchen U., Hamann A., Gutierrez-Ramos J.C., Stahl R.A., Thaiss F. Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int. 2002, 62:1264-1276.
14. Harris R.B., Zhou J., Redmann S.M., Smagin G.N., Smith S.R., Rodgers E., Zachwieja J.J. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998, 139:8-19.
15. Herder C., Brunner E.J., Rathmann W., Strassburger K., Tabak A.G., Schloot N.C., Witte D.R. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009, 32:421-423.
16. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
17. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
18. Hudkins K.L., Pichaiwong W., Wietecha T., Kowalewska J., Banas M.C., Spencer M.W., Muhlfeld A., Koelling M., Pippin J.W., Shankland S.J., Askari B., Rabaglia M.E., Keller M.P., Attie A.D., Alpers C.E. BTBR ob/ob mutant mice model progressive diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:1533-1542.
19. Hughes P.M., Wells G.M., Perry V.H., Brown M.C., Miller K.M. Comparison of matrix metalloproteinase expression during Wallerian degeneration in the central and peripheral nervous systems. Neuroscience 2002, 113:273-287.
20. Hur J., Sullivan K.A., Pande M., Hong Y., Sima A.A., Jagadish H.V., Kretzler M., Feldman E.L. The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 2011, 134:3222-3235.
21. International Diabetes Federation IDF Diabetes Atlas 2013, International Diabetes Federation, Brussels, Belgium, (http://www.idf.org/diabetesatlas). 6th edn.
22. Kang Y.S., Lee M.H., Song H.K., Ko G.J., Kwon O.S., Lim T.K., Kim S.H., Han S.Y., Han K.H., Lee J.E., Han J.Y., Kim H.K., Cha D.R. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 2010, 78:883-894.
23. Keller M.P., Choi Y., Wang P., Davis D.B., Rabaglia M.E., Oler A.T., Stapleton D.S., Argmann C., Schueler K.L., Edwards S., Steinberg H.A., Chaibub Neto E., Kleinhanz R., Turner S., Hellerstein M.K., Schadt E.E., Yandell B.S., Kendziorski C., Attie A.D. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res. 2008, 18:706-716.
24. Kellogg A.P., Wiggin T.D., Larkin D.D., Hayes J.M., Stevens M.J., Pop-Busui R. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes 2007, 56:2997-3005.
25. Lagente V., Le Quement C., Boichot E. Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases. Expert Opin. Ther. Targets 2009, 13:287-295.
26. Malik R.A., Veves A., Walker D., Siddique I., Lye R.H., Schady W., Boulton A.J. Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol. 2001, 101:367-374.
27. Malik R.A., Tesfaye S., Ziegler D. Medical strategies to reduce amputation in patients with type 2 diabetes. Diabet. Med. 2013, 30:893-900.
28. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin. Exp. Immunol. 2000, 121:437-443.
29. O'Brien K., Kim J., Wietecha T., Hudkins K., McDonald T., Minami E., Alpers C. A new murine model of diabetic cardiomyopathy: the female leptin-deficient, black and tan brachyuric mouse. Circulation 2009, 120:S490.
30. O'Brien P.D., Hinder L.M., Sakowski S.A., Feldman E.L. ER stress in diabetic peripheral neuropathy: a new therapeutic target. Antioxid. Redox Signal. 2014, 21:621-633.
31. O'Brien P.D., Sakowski S.A., Feldman E.L. Mouse models of diabetic neuropathy. ILAR Journal 2014, 54:259-272. National Research Council, Institute of Laboratory Animal Resources.
32. Okamoto K., Martin D.P., Schmelzer J.D., Mitsui Y., Low P.A. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp. Neurol. 2001, 169:386-391.
33. Omri S., Behar-Cohen F., de Kozak Y., Sennlaub F., Verissimo L.M., Jonet L., Savoldelli M., Omri B., Crisanti P. Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCzeta in the Goto Kakizaki rat model. Am. J. Pathol. 2011, 179:942-953.
34. Pande M., Hur J., Hong Y., Backus C., Hayes J.M., Oh S.S., Kretzler M., Feldman E.L. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes 2011, 60:1981-1989.
35. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7265-7270.
36. Schmid A.B., Coppieters M.W., Ruitenberg M.J., McLachlan E.M. Local and remote immune-mediated inflammation after mild peripheral nerve compression in rats. J. Neuropathol. Exp. Neurol. 2013, 72:662-680.
37. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes 2003, 52:812-817.
38. Sullivan K.A., Hayes J.M., Wiggin T.D., Backus C., Su Oh S., Lentz S.I., Brosius, F., Feldman E.L. Mouse models of diabetic neuropathy. Neurobiol. Dis. 2007, 28:276-285.
39. Sullivan K.A., Lentz S.I., Roberts J.L., Feldman E.L. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr. Drug Targets 2008, 9:3-13.
40. Tang J., Kern T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30:343-358.
41. Valsecchi A.E., Franchi S., Panerai A.E., Rossi A., Sacerdote P., Colleoni M. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur. J. Pharmacol. 2011, 650:694-702.
42. Verheijen M.H., Chrast R., Burrola P., Lemke G. Local regulation of fat metabolism in peripheral nerves. Genes Dev. 2003, 17:2450-2464.
43. Vincent A.M., Hayes J.M., McLean L.L., Vivekanandan-Giri A., Pennathur S., Feldman E.L. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009, 58:2376-2385.
44. Vincent A.M., Callaghan B.C., Smith A.L., Feldman E.L. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neurol. 2011, 7:573-583.
45. Virella G., Carter R.E., Saad A., Crosswell E.G., Game B.A., Lopes-Virella M.F. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin. Immunol. 2008, 127:394-400.
46. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13:227-232.
47. Wada J., Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin. Sci. (Lond.) 2013, 124:139-152.
48. Wang X., Spandidos A., Wang H., Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 2012, 40:D1144-D1149.
49. Wiggin T.D., Sullivan K.A., Pop-Busui R., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634-1640.
50. Wilson N., Wright D. Inflammatory mediators in diabetic neuropathy. J Diabetes Metab. 2011, S5.
51. Wu L., Fan J., Matsumoto S., Watanabe T. Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. Biochem. Biophys. Res. Commun. 2000, 269:808-815.
52. Xiao X., Ma B., Dong B., Zhao P., Tai N., Chen L., Wong F.S., Wen L. Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. J. Autoimmun. 2009, 32:85-93.